In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViaCyte's potential diabetes 'cure' gets another $6m to move into human trials

This article was originally published in Clinica

Executive Summary

ViaCyte's stem cell-based diabetes product, which the San Diego-based company has said could reduce or eliminate the need for pharmaceutical insulin, has moved into clinical trials earlier than expected, helped by $6 million in new funds. This brings the total invested by the Juvenile Diabetes Research Foundation (JDRF) to $7 million, while the California Institute for Regenerative Medicine (CIRM) has financed nearly $40 million in preclinical work for the VC-01 therapeutic and device combination product.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT099990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel